RE:RE:RE:RE:RE:Lots of good gouge in this article.Solid1 wrote: USC (University of Southern California)
Keck School of Medicine
Treatment of Alzheimer's agitation
disorder
Phase 2 approval by the FDA for an investigational
new drug (IND)
Clinical trial material (‘CTM’)
delivered, and recruitment
began in the 3rd quarter of 2023
The second CTM delivery took place
in the 4th quarter of 2023.
This is an IND and has nothing to do with their pharma partners' applications. The NDA/ANDA run through their pharma partners. The text only tells half the truth
Keck is phase 2 and may as well be eons away in terms of completion. It won't do LABS any good for a long while.
If the Keck trial is indeed the investigational NDA referenced, there is no other NDA in flight apart from the ANDA and we know what that's all about.